Efficacy and Safety of Green Tea Polyphenol in De Novo Parkinson's Disease Patients
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00461942
Recruitment Status :
First Posted : April 18, 2007
Last Update Posted : August 16, 2011
Xuanwu Hospital, Beijing
Ministry of Health, China
Michael J. Fox Foundation for Parkinson's Research
The purpose of this study is to determine whether Green Tea Polyphenol, an extraction from Green Tea is effective and safe in the treatment of De Novo Parkinson's disease Patients without taking any antiparkinsonism drug
Condition or disease
Drug: Green Tea Polyphenols (EGCG/ECG)
The primary outcome measurement is UPDRS using a delay start design. Total 480 de novo PD patients divided into three dosage groups of green tea polyphenol and one placebo control group. Patients will be treated for one year.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
30 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Willing and able to give informed consent
Age 30 years or older at time of diagnosis of Parkinson's disease
Diagnosed as having typical PD
Parkinson's disease duration of no more than 5 years
No current dopaminergic or other forms of anti-parkinsonism therapy